Eli Lilly's Q2 2025 Earnings: Strong Financials Amidst Trial Setback#
Eli Lilly and Company (LLY reported robust Q2 2025 financial results with revenue reaching $15.56 billion, marking a +38% year-over-year increase, surpassing analyst estimates of $14.40 billion. Non-GAAP EPS also beat expectations, coming in at $6.31 versus $5.59 estimated. Despite this solid performance, the company’s stock fell approximately -14% following the release, primarily due to disappointing data from its obesity drug candidate, orforglipron.
Professional Market Analysis Platform
Unlock institutional-grade data with a free Monexa workspace. Upgrade whenever you need the full AI and DCF toolkit—your 7-day Pro trial starts after checkout.
The ATTAIN-1 trial for orforglipron showed an average weight loss of 12.4% over 72 weeks, below the anticipated 15%, coupled with a higher discontinuation rate (10.3% at 36 mg dose) due to adverse events compared to placebo (2.6%). This raised concerns about the drug's tolerability and commercial potential in a competitive market dominated by Novo Nordisk's oral semaglutide. The trial outcome introduced immediate volatility despite the underlying strong financials.
Financial Performance Overview: Revenue, Profitability, and Growth Metrics#
Eli Lilly’s financial trajectory over recent years highlights significant growth and profitability improvements, as demonstrated in the table below:
Monexa for Analysts
Go deeper on LLY
Open the LLY command center with real-time data, filings, and AI analysis. Upgrade inside Monexa to trigger your 7-day Pro trial whenever you’re ready.
| Metric | 2024 (USD Billions) | 2023 (USD Billions) | YoY Growth | 3-Year CAGR |
|---|---|---|---|---|
| Revenue | 45.04 | 34.12 | +32% | +16.73% |
| Operating Income | 17.5 | 10.79 | +62% | N/A |
| Net Income | 10.59 | 5.24 | +102.08% | +23.8% |
| Research & Development | 10.99 | 9.31 | +18% | N/A |
The company’s gross profit margin expanded to 81.31% in 2024, up from 79.25% in 2023, reflecting efficient cost management alongside revenue expansion. Operating margins rose to 38.86%, a notable increase from 31.61% the prior year, and net income margin improved significantly to 23.51%, underscoring enhanced profitability.
Eli Lilly’s aggressive investment in research and development, which consumed ~22.21% of revenue (TTM), supports its pipeline diversification strategy. This R&D intensity is above many peers, reflecting the company's commitment to innovation despite the setback with orforglipron.
Balance Sheet and Cash Flow: Capital Structure and Liquidity#
The company’s balance sheet shows a marked increase in total assets from $64.01 billion in 2023 to $78.71 billion in 2024, driven by capital expenditures and acquisitions. Long-term debt rose from $18.32 billion to $28.53 billion, reflecting strategic investments and acquisition activity.
Cash and cash equivalents increased to $3.27 billion, while total current assets rose to $32.74 billion. The current ratio stands at a healthy 1.28x, indicating adequate short-term liquidity.
Free cash flow (FCF) was positive but subdued at $414 million in 2024, a sharp contrast to the negative FCF of -$3.15 billion in 2023. This swing reflects increased capital expenditures of $8.4 billion, primarily in property, plant, and equipment investments.
| Cash Flow Metrics | 2024 (USD Billions) | 2023 (USD Billions) |
|---|---|---|
| Net Cash from Operations | 8.82 | 4.24 |
| Free Cash Flow | 0.414 | -3.15 |
| Capital Expenditures | -8.4 | -7.39 |
| Dividends Paid | -4.68 | -4.07 |
The company continues to return capital to shareholders, with dividends paid increasing to $4.68 billion and share repurchases totaling $2.5 billion in 2024.
Competitive Landscape: Mounjaro, Zepbound, and Market Dynamics#
Eli Lilly’s growth is heavily supported by Mounjaro and Zepbound, two leading GLP-1 receptor agonists targeting type 2 diabetes and obesity. Mounjaro sales surged in Q2 2025, driven by expanded indications and patient adoption. Zepbound is rapidly gaining market share in the obesity segment, challenging incumbents like Novo Nordisk.
However, the disappointing orforglipron trial highlights the challenges in the obesity drug market, where efficacy and safety profiles are critical. Novo Nordisk’s oral semaglutide remains a dominant competitor with a more established market presence and favorable safety data.
Pipeline and Future Growth Drivers: Donanemab and Beyond#
Beyond obesity, Eli Lilly’s pipeline includes promising candidates such as Donanemab, targeting Alzheimer’s disease. Positive clinical trial results and ongoing phase 3 studies position Donanemab as a potential blockbuster, diversifying the company’s revenue streams.
Additionally, Eli Lilly is advancing therapies in oncology, autoimmune diseases, and rare conditions, reflecting a strategic push for portfolio diversification to reduce reliance on any single therapeutic area.
What This Means For Investors: Navigating Risk and Opportunity#
Investors face a nuanced picture. The orforglipron trial setback introduces uncertainty regarding future growth from the obesity segment, likely contributing to the recent stock volatility. However, the company’s strong core product performance, robust financial growth, and pipeline diversification provide counterbalancing positives.
Key financial metrics underscore Eli Lilly’s strong profitability and capital allocation discipline, despite elevated capital expenditures and debt increases. The company’s return on equity of 88.36% (TTM) and return on invested capital of 27.57% reflect effective management and high-quality earnings.
The company's forward-looking estimates suggest sustained growth, with analysts projecting revenue to reach $60.39 billion in 2025 and EPS of $22.01, with further expansion expected through 2029. Forward P/E ratios are expected to decline from 30.27x in 2025 to 13.43x in 2029, indicating anticipated earnings growth.
Key Takeaways#
- Eli Lilly’s Q2 2025 revenue and earnings significantly beat expectations, driven by blockbuster drugs Mounjaro and Zepbound.
- The orforglipron obesity drug trial results disappointed, causing a sharp stock sell-off despite strong fundamentals.
- The company exhibits robust profitability with expanding margins and high returns on equity and capital.
- Capital expenditures surged in 2024, impacting free cash flow but supporting growth and pipeline expansion.
- Pipeline diversification, including Alzheimer’s drug Donanemab, positions Eli Lilly for long-term growth beyond obesity.
- Competitive pressures in the obesity market remain intense, with Novo Nordisk maintaining a leading position.
- Forward financial estimates suggest continued revenue and earnings growth with improving valuation metrics.
This balanced assessment highlights Eli Lilly’s current strategic strengths and challenges, providing investors with actionable insights amid recent market volatility.